References
- Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15(6):1299–313
- The Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413–46
- Opie LH. Individualised selection of antihypertensive therapy. Drugs 1993; 46(Suppl 2): 142–8
- Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6(Suppl 2): 19–21S
- Kaplan NM. Implications for cost-effectiveness: combination therapy for systemic hypertension. (Editorial) Am J Cardiol 1995; 76(8): 595–7
- Houston MC. Alpha blockers: an effective extension to your patients' risk reduction program. J Clin Pharmacol 1993; 33(3): 264–71
- Houston MC. New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach. Am Heart J 1992; 123(5): 1337–67
- Itskovitz HD. Alpha1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16(3): 490–504
- Minipress (prazosin) prescribing information. Physicians' desk reference. 52nd ed. Montvale, NJ: Medical Economics Co, 1998: 2189–91
- Bockman CS, Jeffries WB, Abel PW. Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther 1993; 267(3): 1126–33
- Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988; 116(6 Pt 2): 1826–32
- Hytrin (terazosin) prescribing information. In: Physicians' desk reference, 9 pp 447–50
- Cardura (doxazosin) prescribing information. In: Physicians' desk reference, 9 pp 2165–8
- Rosenthal J. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. Am Heart J 1988; 116(6 Pt 2): 1763–6
- Troffa C, Manunta P, Dessi-Fulgheri P, et al. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994; 55(1): 22–31
- Englert RG, Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. Am Heart J 1991; 121(1 Pt2): 311–6
- Donnelly R, Elliott HL, Meredith PA, et al. Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992; 19(4): 479–86
- Langdon CG. Doxazosin: a study in a cohort of patients with hypertension in general practice—an interim report. Am Heart J 1991; 121(1 Pt 2): 268–73
- Taylor SH. Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. Am Heart J 1991, 121(1 Pt 2): 362–6
- Grimm RH Jr, Flack JM, Grandits GA, et al, for the Treatment of Mild Hypertension Study (TOMHS) Research Group. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275(20): 1549–56
- Maheux P, Facchini F, Jeppesen J, et al. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension: comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens 1994; 7(5): 416–24
- Neaton JD, Grimm RH Jr, Prineas RJ, et al for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270(6): 713–24
- Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1995; 168: 29–33
- Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28(3): 223–8
- Hilleman DE, Mohiuddin SM, Lusas D Jr, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild to moderate essential diastolic hypertension. (Abstr) Circulation 1992; 88(Pt 2):263